Sequana Medical NV
Brussels Stock Exchange SEQUA.BR
Sequana Medical NV EBITDA for the year ending December 31, 2023: USD -32.16 M
-
Sequana Medical NV EBITDA for the year ending December 31, 2022 was USD -31.24 M, a -23.38% change year over year.
-
Sequana Medical NV EBITDA for the year ending December 31, 2021 was USD -25.32 M, a -17.98% change year over year.
-
Sequana Medical NV EBITDA for the year ending December 31, 2020 was USD -21.46 M, a -38.30% change year over year.
-
Sequana Medical NV EBITDA for the year ending December 31, 2019 was USD -15.52 M, a -4.17% change year over year.
| Date | EBITDA | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) |
|---|
| CEO | Mr. Ian Crosbie |
| IPO Date | Feb. 11, 2019 |
| Location | Belgium |
| Headquarters | Kortrijksesteenweg 1112 |
| Employees | 62 |
| Sector | Health Care |
| Industries | |
Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.
Past 5 years
USD 673.61
StockViz Staff
January 15, 2025
Any question? Send us an email